COVID-19
Conditions
Keywords
COVID-19, Coronavirus infection, Lung abnormalities, Radiological abnormalities, ARDS, Quality of Life
Brief summary
Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
Detailed description
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
Interventions
OTHERCOVID-19
Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
Sponsors
Insel Gruppe AG, University Hospital Bern
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent. * All adult patients with COVID-19 over 18 years.
Exclusion criteria
* Severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection. * Pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary follow-up sequelae in patients after COVID-19 | 36 months | Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging |
| Evaluation of risk factors for adverse Outcome after COVID-19 | 36 months | Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare the radiological Pulmonary outcome of COVID-19 disease | 36 months | Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease |
| Compare the functional Pulmonary outcome of COVID-19 disease | 36 months | Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease |
| Quality of Life after COVID-19 | 36 months | Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease |
| Physical performance after COVID-19 using Clinical Frailty Scale | 36 months | To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease |
| Physical performance after COVID-19 using frailty assessment tests | 36 months | To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease |
| Microbiota and COVID-19 | 36 months | Number of patients with changes in microbiota in response to COVID-19 by microbiota analysis of sputa, bronchoalveolar lavage and swaps |
Countries
Switzerland
Outcome results
None listed